Literature DB >> 22886629

LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators.

Fabrizio Manetti1.   

Abstract

The LIM kinases 1 and 2 (LIMK1 and LIMK2) are dual specificity (serine/threonine and tyrosine) kinases. Although they show significant structural similarity, LIMK1 and LIMK2 show different expression, subcellular localization, and functions. They are involved in many cellular functions, such as migration, cycle, and neuronal differentiation and also have a role in pathological processes, such as cancer cell invasion and metastatis, as well as in neurodevelopmental disorders (namely, the William's syndrome). LIM kinases have a relevant number of known partners that are able to induce or limit the ability of LIMK1 and LIMK2 to phosphorylate and inactivate their major substrate, cofilin. On the contrary, only a limited number of small molecules that interact with the two proteins to modulate their kinase activity have been identified. In this review, the most important partners of LIM kinases and their modulating activity toward LIMKs are described. The small compounds identified as LIMK1 and LIMK2 modulators are also reported, as well as their role as possible therapeutic agents for LIMK-induced diseases.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22886629     DOI: 10.1002/med.20230

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  40 in total

1.  LIMK (LIM Kinase) Inhibition Prevents Vasoconstriction- and Hypertension-Induced Arterial Stiffening and Remodeling.

Authors:  Mariana Morales-Quinones; Francisco I Ramirez-Perez; Christopher A Foote; Thaysa Ghiarone; Larissa Ferreira-Santos; Maria Bloksgaard; Nicole Spencer; Eric T Kimchi; Camila Manrique-Acevedo; Jaume Padilla; Luis A Martinez-Lemus
Journal:  Hypertension       Date:  2020-06-29       Impact factor: 10.190

2.  Quantitative proteomics reveals novel protein interaction partners of PP2A catalytic subunit in pancreatic β-cells.

Authors:  Xiangmin Zhang; Divyasri Damacharla; Danjun Ma; Yue Qi; Rebecca Tagett; Sorin Draghici; Anjaneyulu Kowluru; Zhengping Yi
Journal:  Mol Cell Endocrinol       Date:  2016-01-09       Impact factor: 4.102

3.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

4.  Involvement of LIMK1/2 in actin assembly during mouse embryo development.

Authors:  Xing Duan; Hao-Lin Zhang; Lan-Lan Wu; Meng-Yao Liu; Meng-Hao Pan; Xiang-Hong Ou; Shao-Chen Sun
Journal:  Cell Cycle       Date:  2018-07-25       Impact factor: 4.534

5.  Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.

Authors:  Bryce A Harrison; Zheng Y Almstead; Hugh Burgoon; Michael Gardyan; Nicole C Goodwin; Jason Healy; Ying Liu; Ross Mabon; Brett Marinelli; Lakshman Samala; Yulian Zhang; Terry R Stouch; N Andrew Whitlock; Suma Gopinathan; Beth McKnight; Shuli Wang; Nita Patel; Alan G E Wilson; Brian D Hamman; Dennis S Rice; David B Rawlins
Journal:  ACS Med Chem Lett       Date:  2014-11-24       Impact factor: 4.345

6.  Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.

Authors:  Yan Yin; Ke Zheng; Nibal Eid; Shannon Howard; Ji-Hak Jeong; Fei Yi; Jia Guo; Chul Min Park; Mathieu Bibian; Weilin Wu; Pamela Hernandez; HaJeung Park; Yuntao Wu; Jun-Li Luo; Philip V LoGrasso; Yangbo Feng
Journal:  J Med Chem       Date:  2015-02-04       Impact factor: 7.446

7.  Mitigation of arsenic-induced acquired cancer phenotype in prostate cancer stem cells by miR-143 restoration.

Authors:  Ntube N O Ngalame; Ngome L Makia; Michael P Waalkes; Erik J Tokar
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-22       Impact factor: 4.219

Review 8.  Cofilin and profilin: partners in cancer aggressiveness.

Authors:  Joelle V F Coumans; Rhonda J Davey; Pierre D J Moens
Journal:  Biophys Rev       Date:  2018-07-19

9.  Development of a high-throughput screening method for LIM kinase 1 using a luciferase-based assay of ATP consumption.

Authors:  Mokdad Mezna; Ai Ching Wong; Margaret Ainger; Rebecca W Scott; Tim Hammonds; Michael F Olson
Journal:  J Biomol Screen       Date:  2011-12-07

10.  LIM Kinase, a Newly Identified Regulator of Presynaptic Remodeling by Rod Photoreceptors After Injury.

Authors:  Weiwei Wang; Ellen Townes-Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.